Cancer: Your Next Doctor Might Think Like a Founder

When the system says “wait,” some people start building

Some stories do not merely inspire.

They expose an entire sector.

Not with a slogan.
Not with a glossy conference.
With urgency.

In the materials he has made public, Sid Sijbrandij says that at the end of 2022 he went to the emergency room with pain, that doctors found a 6 cm tumor growing from his spine, and that in 2023 he was diagnosed with high-grade osteosarcoma. He then went through standard-of-care treatment including surgery, radiation, and intensive chemotherapy. According to the National Cancer Institute, localized osteosarcoma is indeed typically treated with surgery, chemotherapy, and sometimes radiation therapy.

Then came the break.

After two years of remission, he describes a local progression in 2024 and condenses the turning point into one chilling line: “You’re done with standard of care. Good luck!” In his own telling, that is the moment he stopped behaving like a passive patient waiting for the system to run its sequence and started acting like a founder rebuilding the operating model around survival.

That shift deserves the attention of every executive.

Because at that moment, he does not simply seek another treatment.
He redesigns the decision process itself.
He measures more.
He tests more.
He opens more options.
He accelerates.

And suddenly, what many companies still call innovation starts to look like theatre. (Sytse, Century of Bio)

Founder mode applied to survival

In his presentation, Sid Sijbrandij frames his approach around four pillars: maximal diagnostics, making treatments, treatments in parallel rather than serial, and scaling for others. He also states that he has made 25 TB of data publicly available through osteosarc.com, and he describes an approach involving DNA/RNA sequencing, single-cell sequencing, frequent MRD testing, targeted radiodiagnostics, and more than 10 personalized drugs and diagnostics. The National Cancer Institute defines precision medicine as medicine that uses information about a person’s genes, proteins, environment, and lifestyle, and in cancer specifically about the tumor, to guide diagnosis, treatment, monitoring, and prognosis.

What stands out here is not only medical complexity.

It is the mental architecture.

Many organizations still operate like a queue:
observe first,
validate later,
test eventually,
deploy one day,
learn when the window has almost closed.

He operates differently:
multiply signals,
expand optionality,
reduce blind spots,
reject the single-scenario mindset,
treat time as a strategic variable.

In my book, chapter 17, I explain that biohacking rests on vision, methods, experiments, and learning. This story reads like a full-scale demonstration of that principle.

What this reveals about modern medicine

This story does not prove that every patient can or should replicate such an approach.
It reveals something else.

It reveals what becomes visible when the stakes turn existential: fragmentation, sequential logic, administrative drag, information asymmetry, and limited access to experimental options.

The FDA itself states that expanded access may be appropriate when a patient has a serious or immediately life-threatening disease, no comparable or satisfactory alternative exists, clinical trial enrollment is not possible, and the potential benefit justifies the potential risk. The agency also describes the single-patient IND pathway for individual patients.

In other words, even regulators acknowledge that the default system does not cover every urgent human reality.

What Sid’s story puts on the table is the gap between a system designed for average safety and a life that is singular, time-constrained, and deeply personal.

That gap is not unique to medicine.

It appears anywhere institutions are optimized to administer the normal while reality demands faster action on the exceptional.

The deadly trap of sequential thinking

One of the strongest ideas in his presentation is brutally simple: “Treatments in Parallel, Not Serial.” He also writes that many people run out of time before finding a cure and that there is no real incentive to test treatments together. Whether one agrees with every implication or not, the management lesson is huge: in some situations, the order of testing is itself a strategic risk.

That is exactly what many companies still fail to understand.

They think they are reducing risk by sequencing everything.
What they actually do is relocate the risk.
They reduce internal decision discomfort.
They increase external obsolescence risk.

They protect process.
They lose tempo.

And tempo now matters everywhere:
AI, biotech, energy, defense, media, education, finance, healthcare.

The danger is no longer only being wrong.
The danger is understanding too late.

Open data, open options

Another signal matters: data openness.

Sid points publicly to osteosarc.com and to a large openly readable dataset. That logic aligns with the broader stance of the NIH, which states that sharing scientific data accelerates biomedical research discovery, improves rigor and reproducibility, increases access to high-value datasets, and promotes reuse in future studies.

This is where many organizations are still trapped in contradiction.

They talk about collaboration.
They keep data in silos.
They talk about transformation.
They let critical information sleep.
They talk about faster decisions.
They make access to reality painfully slow.

The moment an organization closes the flow of information, it also closes the field of options.
And once optionality narrows, speed becomes a slogan instead of a capability.

The message executives should not ignore

The point is not that companies should “play doctor.”
The point is to understand what this story makes impossible to ignore.

An effective founder does not worship protocol.
He respects rigor.
He still questions the order of operations.
He seeks the best real path, not the default administrative path.

That is where many leadership teams fail.

They believe they are managing innovation because they fund a few pilots, open a lab, launch a committee, invite a couple of experts, and ask for quarterly reporting.

Meanwhile, weak signals accumulate.
Competitors experiment.
Customers shift.
Usage changes.
Markets rewrite the rules.
And the company remains busy asking permission to look.

What organizations should copy immediately

Not the medical condition.
Not the suffering.
Not the biography.

The operating frame.

Capture more useful signals.
Create more options instead of defending one hypothesis.
Accept that some experiments must run in parallel.
Move data faster.
Decide before bureaucratic comfort reaches perfection.

The OECD definition is useful here: innovation is not a decorative idea. It is a new or improved product or process that has been made available to users or brought into use. Innovation begins at implementation, not at commentary.

That is why this story extends far beyond medicine.
It points toward the next frontier of management: decisions strengthened by data, experimentation, and coordinated action.

The future will not belong to the most cautious structures

It will belong to the structures capable of being rigorous without becoming immobile.

Useful caution measures better.
Toxic caution delays everything.
The first protects the future.
The second mostly protects habits.

Your next doctor may not literally be a founder.
But many leaders will have to learn to think as if their organization depended on the same level of strategic intensity.

Because in every sector, sooner or later, reality enters the room and says:
the standard of care is no longer enough.

From that moment on, two kinds of organizations separate.

Those waiting to be saved.
And those building their odds.

References

(Sytse) = https://sytse.com/cancer/
(Century of Bio) = https://centuryofbio.com/p/sid
(Osteosarc) = https://osteosarc.com/
(National Cancer Institute – Precision Medicine) = https://www.cancer.gov/publications/dictionaries/cancer-terms/def/precision-medicine
(National Cancer Institute – Osteosarcoma Treatment PDQ) = https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq
(FDA – Expanded Access) = https://www.fda.gov/news-events/public-health-focus/expanded-access
(FDA – Single Patient Expanded Access) = https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use
(NIH – Scientific Data Sharing) = https://osp.od.nih.gov/policies/scientific-data-management-policy/
(OECD) = https://www.oecd.org/en/publications/oslo-manual-2018_9789264304604-en.html

Picture of Philippe Boulanger

Philippe Boulanger

Philippe Boulanger, international speaker on innovation and artificial intelligence, author, advisor, mentor and consultant.

Latest POSTS

Adobe Kickbox: $1,000 to Test an Idea Without Permission

At Adobe, any employee can receive a red box with $1,000 to spend without approval to test an idea. What’s inside, the six levels of the journey, what Swisscom, Cisco and LinkedIn took from it, and the trap of free time that evaporates.

Read More »

Guest Checkout: The Button That Lifted Sales by 45%

A “Register” button replaced by “Continue,” and 45% more buyers according to Jared Spool. The $300 million figure can’t be verified, but the friction it exposes still sits in your checkout today.

Read More »

41 Shades of Blue: Google’s $200 Million A/B Test

By testing 41 shades of blue, Google claims it earned an extra $200 million a year. Behind the cult A/B testing anecdote lies a debate every leader has to settle: when to trust the data, and when it stops you from innovating.

Read More »

Drone vs Camera Robot: Who Films Where the Sky Is Banned?

Banned from flying over crowds, drones run into regulation and noise. The Beni camera robot films from the ground. A textbook case of the framing bias.

Read More »

Friday the 13th: why superstition pays off for innovators

Friday the 13th destroys nothing. People who fear it change their behavior, and that change can be measured. Accidents, stock markets, the Jerusalem virus, a $900 million figure nobody verified: what superstition reveals about your innovation decisions, and how to use it.

Read More »

Naming an innovation: what Sapir showed in 1929

In 1929, Edward Sapir showed that most people link the invented word “mal” to a large table and “mil” to a small one. Almost a century later, sound symbolism still shapes how we perceive product names. What the numbers really say, what marketing took from it, and how to test a name before you pick it.

Read More »

AI-Generated Code: Who Still Understands Your Software?

A year after handing 100% of its code to AI, a company finds that nobody can explain it anymore. An anonymous testimony, the METR, GitClear and Veracode studies, and the method to stay out of the labyrinth.

Read More »

Why Coca-Cola’s Inventor Never Got Rich

John Pemberton invented Coca-Cola in 1886 and died poor two years later. Thirty-three years after the first glass, the company was worth $25 million. What this story reveals about the difference between invention and innovation, and about the Pemberton who may be sitting in your own company.

Read More »

Are you a rule breaker?

You weren’t supposed to find this.

But here you are, because you did what most people don’t: you questioned, you explored, you clicked the thing you weren’t sure you should click.

That’s Innovational Intelligence™ in action.

Most people stay inside the lines. Follow the expected path. Click the obvious buttons. Accept things as they are.

Not you.

You’re one of those rare minds that refuses to accept “this is how it’s always been done.”

We need more people who think like you.

So here’s your reward for coloring outside the lines:

Get VIP pre-release access to the next assessment on Innovational Intelligence™:

You’ll be the first to know when it’s available.

Keep breaking rules. The world needs what you see.

Your daily dose (or almost) of Innovational Intelligence™!

Receive in your inbox my latest post before everyone else!